Skip to main content
Premium Trial:

Request an Annual Quote

Metabolomics IMSB'S Sauer uncovers roles for Doppelganger genes

Premium

In the six months since Uwe Sauer joined ETH Z rich’s Institute of Molecular Systems Biology, he’s managed to put together a lab, publish more than a dozen research publications, and complete the largest functional classification of duplicate genes to date.

Apparently it’s not the Swiss air that fosters such prolificacy, but rather the fact that Sauer’s five-year quest to “develop technology for the global assessment of molecular traffic” has culminated in a complex of tools and methods ideal for tackling questions in metabolomics. Molecular flux analysis — tracking carbon molecule traffic within cells via the use of carbon-13 labeling and sensitive mass spec, then fitting that data to a mathematical model — is a key approach in Sauer’s repertoire.

In a recent paper for Genome Research, Sauer’s team looked at the phenomenon of functional gene duplicates involved in yeast metabolism. Contrary to previous reports that focused on a single mechanism responsible for the retention of duplicates, Sauer’s group found that “at least for yeast metabolism, the persistence of the duplicated fraction of the genome can be better explained with an array of different, often overlapping functional roles,” he says. That array of roles includes four distinct mechanisms that were uncovered by looking at quantitative measurements, such as flux, in terms of computational models, he says.

For future research lines, model microbes like yeast will almost certainly remain in a starring role, but moving into more complex systems is one of Sauer’s goals. That said, he affirms that “any higher cell is in a totally different situation.” Carbon molecule traffic changes constantly in higher systems, he says, so it is necessary to develop new methods before moving away from yeast.

“That’s what really drives us as a group,” Sauer says about the integration of information gleaned from various sources. Since joining Ruedi Aebersold at IMSB in July, Sauer has continued to “develop technology and try to apply it to industrial process development, but also to medically related problems.” Lucas Pelkmans, the institute’s RNAi expert, started a lab one month after Sauer, and the three PIs are actively working to foster “cutting-edge technology development.”

— Jen Crebs

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.